Having allergies are common to most people. What sets them apart from each other are the triggers in the environment that actually cause the allergic reaction. These reactions are physiologically determined by varying stimuli, such as dust or airborne pollutants, which cause the release of the biogenic amine called histamine. The histamine circulating the blood binds to the mast cells of different tissues and causes the symptoms we know call “allergic responses.” Some allergic responses include red eyes, flushing of the cheeks, sneezing, and inflammation of the sinuses known as sinusitis. Although different environmental stimuli could cause allergic reactions, it should be noted that when left untreated, all of these stimuli could cause harmful infections that would possibly require surgical treatment.
A different kind of approach is now recently being undergone by Dr. Bradley Chastant, a surgeon in Lafayette, Louisiana, where he has developed the use of a new kind of medicated stent that promises to treat patients with chronic allergic attacks. He has been developing this new technique for over a decade now, and he has already become the first to perform this procedure at Lafayette General Surgical Hospital. An implantation device called Propel is now being used to treat long-term sinusitis of patients who are about to go under the knife. The implant is readily dissolved after the surgery is completed, which means that the drug release is time-controlled and that the area of effect is localized to efficiently maximize the drug’s capabilities. This timed-release, according to clinical trials, ensures the unblocking of the ethmoid and frontal sinuses post-operation, thereby eliminating the chances of subsequent surgeries.
Dr. Chastant explains that immediately after the surgery, the use of the medicated stents greatly reduces the chance of restenosis occurring, thereby increasing the comfort of the patient suffering from chronic ethmoid sinus inflammation. In addition, the stenting of the frontal sinus also reduces the chance of the sinusitis from ever coming back, which takes away the need to use antibiotics to reduce the swelling of the sinuses.
Dr. Jeffrey Joseph and Dr. Jennifer Hanby are working with Dr. Chastant in producing researches related to allergic responses, along with their early diagnosis and possible cures. The fruits of their research have currently produced this new medical stent that is of a corticosteroid-base and has an anti-swelling effect on the targeted sinus with the inflammation. This gives patients with chronic problems a sigh of long-term relief from all the sneezing and watery eyes.
Dr. Chastant and his colleagues believe that the development of this new technique has the capacity to affect many lives. One such patient who has had the privilege of undergoing the procedure for 11 years already said that the disparity between his disease prior the use of the stent and after implantation is stark. He said that he used to have a lot of surgeries before the treat for his allergies and asthma—all of which only provided relief for a short period of time. Now, thanks to the new stent technique, he was relieved of his sinusitis and asthma for a long-term basis.
Constantly monitoring the degree of improvement of their patients is what drives Dr. Chastant to research more on the possible treatment of allergies. He said that he enjoys the fact that patients are having a whole new outlook in life thanks to the procedures done by him and his peers. Dr. Chastant’s end objective is to develop a procedure that reduces the risks of sinus closure post-operation and returning of the allergy, while at the same time restoring the comfort which the patient has had prior the development of the allergy. So far though, he is on the right track in achieving this goal.








